OpenAI 收购 Orchestra Bio,将 AI 引入药物研发
OpenAI acquires Orchestra Bio
OpenAI 把 Orchestra Bio 收进来了,以后做药的公司能用他们的 AI 加快药物研发,生物医药的朋友可以关注下。
OpenAI 宣布收购 Orchestra Bio,目标是把 AI 运营能力引入生命科学研发领域。交易完成后,OpenAI 将帮助生物制药团队加速药物开发流程、推进新疗法研究。这是 OpenAI 继多家科技公司并购之后在生命科学方向的一次布局。
OpenAI acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.